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Microvessel density predicts survival in prostate cancer
patients subjected to watchful waiting
M Borre1.2, BV Offersen', B Nerstr0m2 and J Overgaard'
The Danish Cancer Society. Departments of 'Experimental Clinical Oncology and 2Urology. University Hospital of Aarhus. Denmark
Summary The biological potential of prostate cancer is highly variable and cannot be satisfactohly predicted by histopathological criteria
alone. Angiogenesis, the formation of new blood vessels, has been suggested to provide important prognostic information in prostate cancer.
The aim of this study was to investigate whether microvessel density (MVD) at diagnosis was correlated with disease-specific survival in a
non-curative treated population of prostate cancer patients. MVD was immunohistochemically (factor VIII-related antigen) quantified in
archival tumours obtained at diagnosis in 221 prostate cancer patients. Median length of follow-up was 15 years. The maximal MVD was
quantified inside a 0.25 mm2 area of the tumour and the median MVD was 43 (range 16-151) mm2. MVD was statistically significantly
correlated with clinical stage (P < 0.0001) and histopathological grade (P < 0.0001). When dichotomized by the median counts, MVD was
shown to be significantty associated (P = 0.0001) with disease-specific survival in the entire population as well as in the theoretically curable
clinically localized subpopulation. A multivariate analysis demonstrated that MVD was a significant predictor of disease-specific survival in the
entire cancer population (P = 0.0004), as well as in the clinically localized cancer population (P < 0.0001). These findings suggest that
quantitation of angiogenesis reflects the spontaneous clinical outcome of prostate cancer.
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Prostate cancer has become one of the most common malignant
diseases in Western countries. In Danish men. prostate cancer is
the second most commonly diagnosed non-skin cancer disease
(Engeland et al. 1993) and the second leadincg cause ofmale cancer
death (Engeland et al. 1995). Nevertheless. the frequency of latent
carcinoma of the prostate at autopsv has been found to be manx
times greater than w-ould be expected from the incidence and
mortalitv of clinical prostate cancer (Breslow- et al. 1977). The
present capability to identifx prostate cancer patients at an earlv
and theoreticaflx curable stage. without beinc able to discriminate
between latent and potentially aggressixe tumours. has resulted in
the present dilemma of this cancer disease (Borre et al. 1998).
Therefore. to make an aggressive therapeutic approach to1k-ards
localized prostate cancer beneficial. development of sensitive
prognostic new markers is ofgreat importance.
Experimental evidence has demonstrated that tumour growth
and dissemination are dependent on anriogenesis. the formation of
new blood vessels from an extant microvascular bed (Folkman.
1990). MicroVessel densitv (MVD) has been shown to correlate
w-ith the clinical outcome of several human neoplasms. e.g. cuta-
neous melanoma (Srivastava et al. 1988) and breast carcinoma
(Weidner et al. 1991: Fox et al. 1994: Heimann et al. 1996). In
prostate carcinoma. MVD has been show n to correlate with stage
(Weidner et al. 1993: Brawer et al. 1994). as well as progression
after radical prostatectomy (Silberman et al. 1997).
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The purpose of this study %vas to investigate the association
betnveen MVD and the clinical stage. histopathological grade and
survival in patients with prostate cancer followed expectantly.
MATERIALS AND METHODS
Patients
A complete population of patients with prostate cancer consisting
of 719 inhabitants of Aarhus County xxere diagnosed in a 5-xear
period (1 Januarx 1979 to 31 December 1983). The patients haxe
been retrospectively followed from the time of diagnosis until
death. From this previously described prostate cancer patient
population (Borre et al. 1997). 221 patients (31%7c). irrespective of
tumour stage. were included in the present studx. Thex represent a
cohort xxith axvailable histological tumour tissue obtained at diag-
nosis as w-ell as complete clinical information. The tumours have
been retrospectively classified (Borre et al. 1997) according to the
tLICC 1992 classification system (Hermanek and Sobin. 1992).
x hereas the orininal histopathological malignancy grade
according to WHO (Mostofi et al. 1980) was used. The patients
have been followed expectantly and their symptoms treated pallia-
tivelv only. A total of 108 (49%c) patients received endocrine treat-
ment durinc disease.
Specimens
Transurethral resected prostate (TURP) specimens for the
immunostaininc procedures were retrieved from the formalin-
fixed. paraffin-embedded tissue used for the original histopatho-
logical grading. Without know-ledge of the clinical outcome. one
representatixe section (4 gm thick) per patient w-as chosen. The
study was carried out w-ith ethics comnmittee approval.
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FIgure 1 Photograph shows micrvessels itiied by mst
endoftelial cels for Factor ViII-related antg in prostate cancer. Bar,
0.1 mm. The area shown equalizes the counting area at x 200 mnagnification
(0.25 mm2)
vWF-8 immunohistochemical assay
Microvessels were highlighted by staining endothelial cells for von
Wlllebrand factor (vWF. Dako polyclonal P226. Dako. Denmark).
Afterdeparaffinization andrehydration. the tissue was microwaved
in abufferof 10 nrm sodium citrate. pH 6.0. for3 x 5 min at650 W.
After 20 min cooling at room temperature. the slides were rinsed
with Tris-hydroxymethyl)aminomethane. Sigma 7-9 (Tris). and
phosphate-buffered saline (PBS) 1:9. The tissue was then incubated
in 2% hydrogen peroxide in ethanol (99%) for 20 min at room
temperature. followed by incubation with the peroxidase-conju-
gated primary antibody (vWF. Dako polyclonal P226. Dako)
diluted 1:30 in antibody diluent code S0809. Dako. for 18 h at 40C
in a humidity box. The slides were rinsed twice for 5 min in
Tris/PBS and incubated for 10 min in 5 ml of 0.8% 3-amino-9-
ethylcarbazole (Sigma a-5754) solution, diluted 1:20 in acetate-
buffered saline and 3gil hydrogen peroxide was added. As the end
products were soluble in organic solvents, an aqueous counterstain
with Mayer's haematoxylin and a Dako Glycergel (code no.
C0563) was finally used.
Quanttaton of MVD
The most vascularized areas ( hotspots') were identified using a
low high-power field magnification (x 40- x 100). The MVD was
quantified at both x 200 and x 400 magnification high-power field
(x 10 ocular and x 20/x 40 objective) using a 10 x 10 grid in the
eyepiece. The grid covered an area of 0.25 and 0.0625 mm2
respectively. Any red-stained vessels that were clearly separated
from adjacent microvessels. occurring within the grid. were then
counted. The presence of a vessel lumen was not necessary
although usually present (Figure 1). The blinded procedure was
done by a single observer (MB). The method was validated in a
methodical study (Offersen et al. 1998).
Statistical analysis
Statistical analysis was performed using the SPSS 6.1 for
Windows (SPSS. Chicago. IL. USA) program package. The two-
sided chi-squared test was used to test for an association between
categorical data and the Spearman rank-correlation coefficient was
used to characterize the correlation between ordinal and contin-
uous variables. The survival functions were calculated according
to the method of Kaplan and Meier and the differences between
the survival curves were tested by the log-rank test. The Cox
proportional hazards regression model was used to analyse the
prognostic value of the clinical characteristics determined at the
time ofdiagnosis. Disease-specific death was defined as all deaths
caused directly by prostate cancer excluding deaths from
coexisting disease. accidents and unknown causes. All P-values
were based on two-sided testing.
RESULTS
At the time of diagnosis. the median age was 75 years (range
49-95 years) and at the end of registration (May 1996) 215
patients (98%) had died. According to the hospital charts and
death certificates. 125 patients (57%) had died from prostate
cancer, while 90 patients (41%) had died from other causes. The
median time to death for those who died was 3.5 years (range
0.01-15.6 years).
Table 1 demonstrates that there is no significant difference in
the distribution ofclinical characteristics between the original and
the current populations. At the time of diagnosis 125 patients
(57%) suffered from clinically localized (T1-2. Nx. MO) disease.
while 96 patients (43%) had either locally advanced or dissemi-
nated (T > 2. Nx and/or Ml) disease.
At x 200 magnification (0.25 mm2). the median MVD was 43
(range 16-151: Figure 1) and at x 400 magnification (0.0625 mm2)
the median MVD was 17 (range 6-60). There was a good correla-
tion between the two counting areas (0.25 mm' or 0.0625 mm2)
(Spearman correlation coefficient = 0.88; P < 0.001). Irrespective
of the counting area. the MVD was highly significantly associated
with clinical stage (P < 0.0001), histopathological malignancy
grade (P < 0.0001) and cause of death (P < 0.0001). Taking this
mutually significant accordance of the MVD based on both
counting areas into consideration, the following text and analyses
refer to MVD as detennined at x 200 magnification (0.25 mm2).
MVD was dichotomized using the median count as the cut-off to
define MVD 'low' and 'high'. Table 1 demonstrates the distribu-
tion ofMVD 'low' and 'high' and the clinical characteristics in the
entire prostate cancer population. as well as in the subpopulation
consisting of patients with theoretically curable clinically local-
ized disease. MVD was significantly (P < 0.0001) associated with
all characteristics in all 221 patients. while a similar correlation
was less pronounced in the subgroup of patients with clinically
localized disease. MVD remained statistically associated with the
cause ofdeath (P = 0.0005) and none ofthe patients categorized as
MVD 'high' survived the observation period. No statistically
significant difference (P = 0.7) was found between the MVD cate-
gories 'low' and 'high' for age at presentation of prostate cancer.
MVD was associated with both overall (P < 0.0001) and disease-
specific survival (P <0.0001) in the entire population (Figure 2A).
Focusing solely on the 125 patients with clinically localized
prostate cancer. MVD was found to be significantly (P = 0.0001)
correlated with disease-specific survival only (Figure 2B). while
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Table 1 Clinical characteristics at diagnosis and cause of death in the previously described original complete prostate cancer population (Borre et al. 1997).
compared with the current subpopulation: all 221 patients irrespective of tumour stage and the 125 patients with dinically localized (T1-2. Nx, MO) prostate
cancer categorized by microvessel density 'ko# and 'high (based on the median scores)
PC populaions M dens
Original Curnt All PC pabents (n = 221) Clinically localized PC pabents (n = 125)
Characterisic n (%) n(%) 'Low' 'High' P-value 'Low' 'High' P-value
Total 719 (100) 221 (100) 114 (52°o0) 107 (480o) 63 (50%c) 62 (500°o)
T-class
Tla 45 (6) 21 (10) 17 (15%c) 4 (4°h) <0.0001 14 (22%) 7(11°co) = 0.21
Tlb 166 (23) 83 (38) 55 (48%) 28 (260c0) 40 (64%c) 42 (68°0c)
T2 90 (13) 27(12) 14(120Cc) 13(12Cc) 9(14°0) 13(21°o)
T > 2 367 (51) 90 (40) 28 (25°h) 62 (58%) - -
Tx 51 (7) 0 (0)
M-class
MO 306 (42) 161 (73) 96 (840o) 65 (61°o) <0.0001 63 (50°o) 62 (50eo)
Ml 240 (33) 60 (27) 18 (16%10) 42 (39%) - -
Mx 173 (24) 0 (0)
Clinical stage
T1-2, MO 224 (31) 125 (57) 85 (75°o) 40 (370) <0.0001 63 (50°o) 62 (50Cc)
T> 2 andJor Ml 418 (58) 96 (43) 29 (25°0) 67 (63Co) - -
Grade
Well 142 (20) 59 (27) 46 (40°o) 13 (12co) <0.0001 37 (59°o) 15 (24co) = 0.0003
Moderate 184 (26) 90 (41) 43 (38%) 47 (440o) 19 (30Cc) 29 (47%)
Poor 171 (24) 72 (32) 25 (22%) 47 (44°o) 7 (11°o) 18 (29°o)
Unknown 222(30) 0 (0)
Cause of death
Prostate cancer 444 (62) 125 (57) 42 (37%c) 83 (78°o) <0.0001 15 (23°o) 36 (580o) 0.0005
Other causes 258 (36) 90 (41) 66 (58%) 24 (22°o) 42 (679co) 26 (42°o)
Alivea 17 (2) 6 (2) 6 (5%) 0 (0°°) 6 (10Co) 0 (0°°)
PC. prostate cancer. a Excluded from statistical (chi-squared) test.
no such correlation (P = 0.07)existedAiIth overall survival. Figure
2C demonstrates the significant (P < 0.0001) correlation between
MVD and disease-specific survival in 96 patients suffering from
advanced disease. The association betseen MVD and overall
survixal w-as also significant (P = 0.0001) within the same
subgroup of patients.
Table 2 demonstrates the results of unixvariate and multivariate
analyses using disease-specific deaths as endpoints. Analysis (A)
includes all 221 prostate cancer patients. while analysis (B)
focuses solely on patients with clinically localized disease. MVD
A-as found to offer predictiN-e value in both populations and. in the
subpopulation sufferinc from clinically localized disease. MVD
was the only significant (P < 0.0001) predictor ofdisease-specific
survival (Table 2B). By analysing MVD as a dichotomized
low/high' parameter instead of as a continuous parameter. the
relatix-e risk in. forexample. the clinically localized cancer patients
A-as 3.84 (95% confidence interval 2.17-6.82) without changing
the results of the remaining parameters.
The patients were subjected to watchful w-aiting and treatment
A-as offered only on occurrence ofsymptoms. Nearly half(49c%c) of
the patients received endocrine palliative treatmentduring disease.
and the disease-specific survival rates among these patients were
significantly (P = 0.04) shorter than amongy those who did not need
palliative treatment. There was a slight majority (55%cc) of MVD
*high' tumours in the group ofpalliated patients. while 58%c ofthe
tumours in the group ofnon-palliated patients were categorized as
MVD low'. However. there remained a significant difference in
disease-specific sun-ival between MVD 'high' and MVD 'low
tumour patients. testing the treatment-demanding (P <0.0001) and
the untreated patients (P = 0.0005) separately.
DISCUSSION
Despite established prognostic criteria in prostate cancer patients.
a confident prediction of the clinical outcome in the indixidual
patient is often not possible. This circumstance makes additional
prognostic information necessary.
To our knowxledge. angiogenesis has not previously been corre-
lated with sur ival in prostate cancer patients. This study was based
on a previously described complete prostate cancer population
subjected to watchful waiting (Borre et al. 1997). The present
subpopulation represents patients with available archival histolog-
ical tumour samples obtained at the time of diagnosis as well as
complete data records. The follow-up data were almost complete
and the cause of death ratio was nearly identical in the current
subpopulation and the original population (Table 1). Retrospectively
obtained information will nexerbe ideal. andunderstagingas well as
inaccuracy of determination of the cause of death are well-known
problems. However. the advantage of retrospective studies is that
long-term followv-up is available immediately. Unfortunatelv.
prostate-specific antigen was not axailable at the time ofdiagnosis.
As the patients were subjected to watchful waiting. endocrine
therapy was a surrogate marker for bad prognosis. Therefore.
endocrine therapy w-as not included in the survival models.
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Table 2 Univariate and Cox multivariate analyses of the prognostic value of
clinical characterisics and microvessel density for disease-specific survival in
(A): 221 prostate cancer patients irrespective of clinical stage, and (B): 125
prostate cancer patients with clinically localized (T1-2. Nx. MO) disease
Mulftivariate
Univariate
Factor P-value P-value RR Cl (95%)
A
TclasSificationa < 0.0001 < 0.0001 1.89 1.53-2.32
M-Classification < 0.0001 0.25 -
Grade- <0.0001 0.03 1.33 1.03-1.72
MVDI <0.0001 0.0004 1.01 1.01-1.02
B
T-cassificatione 0.03 0.06 - -
Grade- 0.004 0.10 -
MVEd <0.0001 <0.0001 1.03 1.02-1.05
aT1a vs T1b vs T2 vs T > 2. "MOvs M1 cWell vs moderate vs poor
differentiation. WMicrovessel density (continuous parameter. area =
0.25 mm2). eTla vs Tlb vs T2. RR, relative risk: Cl. confidence interval.
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Figure 2 The microvessel density (MVD) divided into (a) low and (b) high
by the median count inside 0.25 mm2 tumour 'hot spotf areas correlated with
disease-specific survival in (A): all 221 patients with prostate cancer
irrespective of tumour stage (MVD median 43); (B): 125 patients with
clinicalty localized prostate cancer (T1-2. NX. MO; MVD median 37): (C): 96
patients with advanced prostate cancer (T> 2 and/or Ml. MVD median 53)
Based on the knowledge of the great heterogeneity of prostate
cancer (Bvar and Mostofi. 1972) and the demonstration ofa sianif-
icantlvhigher MVD at the centre ofthe prostate tumour than at the
pernphenr (Siegal et al. 1995). the MVD was quantified as the
maximum count in microvessel positive 'hotspot areas of the
tumour.
As a cut-off point representing the median *-alue can be used
without introducing bias evaluating prognostic factors (Simon and
Altman. 1994) MVD 'lo, and 'high' groups were defined by
dividing the patients into two equal groups using the median
MVD. The survival plots in Figure 2A-C represent three different
median values as cut-off points. If. however. the cut-off point of
the entire population (median = 43) had been applied to the
subpopulations. the significant difference in survival would not
have changed. although the distribution ofthe patients would have
been different. In the multivariate analyses (Table 2). MVD was
preferred to be analysed as a continuous parameter to retain all the
information (Simon and Altman 1994) and the relative risk
therebv refers to every single additional microvessel count.
However. when analysing MVD as a dichotomized Iow/hi5h'
parameter. the relative risk resembled the results found by. for
example. Heimann et al (1996) and Fox et al (1994).
Like Weidner et al (1993) who used a larger counting area
(0.739 mm') to estimate the maximal MVD in 79 prostate cancer
patients. the current study found a statistically significant associa-
tion between MVD and increase in both clinical stage and malig-
nancy grade. Weidner et al (1993) found a median MVD per mm'
in patients with and without metastases reaching. respectively. 49
and 89 against 160 and 232 in our study (based on the 0.25 mm
counting, area).
Counting randomlv selected tumour areas by computer. Brau-er et
al (1994) successfully demonstrated that MVD was a significant
predictor of pathological stage in 37 prostate cancer patients. By
converting the raw data. measured in the 1.71-mm area. to vessels
permm. the mean MVD oflocalized tumours was 80compared with
110 for tumours with capsular penetration in the same study (Brawer
et al. 1994). By a similar conversion ofthe NVDoriginally measured
in both areas in the current studv. the ratios of the mean MVD per
mm'between organ-confined and non-organ-confined tumours were
nearlv identical (about 0.7) to the result ofBraweret al (1994).
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Silberman et al ( 1997) have demonstrated that MYD correlates
wvith progression after radical prostatectomy in 87 carcinomas.
The anti-CD31-immunostained microVessels were quantified in
'hotspot' areas (3.14 mm'). The same studv failed to demonstrate a
correlation between angiogenesis and pathological stage. However.
only intermediate-grade carcinomas were included in the study.
There exist no absolute cut-off numbers for MVD to predict
prognosis that have held up across different studies which are in
anv case difficult to compare directly because ofthe differences in
counting areas. Despite the fact that MVD per mm' is dependent
on the original countingy area. we only found marginal differences
in the distribution of the patients in MVD low' and 'high' cate-
,gories. using either a 0._5-mm' or a 0.0625-mm' area. Although
determination of MVD is far from standardized. the current results
were based on the MIVD determination at x200 magnification.
However. the smallest counting area was slightly superior to the
larger when comparing the significance between MVD and clin-
ical outcome in a multivariable analysis. A similar observation.
that a small area corresponding to a highermagnification improves
the detail ofthe image. thereby allowina the identification of more
single endothelial cell sprouts. has been made in breast cancer
(Vermeulen et al. 1996). However. information will be lost if the
counting areas do not match the size of the hotspots. As proposed
by Vermeulen et al (1996). a standardization ofangiogenesis quan-
tification is necessan to facilitate confirmation of the sugagested
prognostic value ofMVD in prospective controlled trials. By stan-
dardizinu and simplifying the scoring of MVD. it will probably
become a useful and important progynostic marker in future. It
should be emphasized that the current data are based on material
primarily removed by TUtRP. while the future clinical utility of
MVD. together with several other prognostic mark-ers. will be
dependent on biopsy techniques. which migrht tum out to be a
critical issue caused by the relative lack of material from this
distinctly heterogeneous cancer.
Despite the risk of inaccuracy in data due to retrospectively
obtained patient characteristics. as well as immunohistochemical
quantification of angiogenesis. the current results of the associa-
tion between angriogenesis as measured by MVD and survival in
patients subjected to watchful waiting suggest that the pattem of
neovascularization is important in the natural historv of prostate
cancer. Angiogenesis. as a predictor of the spontaneous clinical
outcome of clinically localized prostate cancer patients. should be
included in the decision of future therapeutical strategies of the
individual prostate cancer patient.
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